Analysis & ranking
PHASE 2 — Evidence and Impact Analysis
Article 1 — Kanellopoulos et al. — NMA vs. RIC conditioning in elderly AML allo-HCT (PMID 42324362)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Largest registry study to date (n=2,900) on this comparison; PBSC survival advantage finding is new and operationally important |
| Clinical Relevance | 8 | Directly informs conditioning and graft source selection in elderly AML transplant candidates — a daily decision point |
| Population Reach | 6 | Elderly AML is a sizable but defined subpopulation; ~20,000 new AML diagnoses/yr in the US, ~40% in patients ≥65 |
| Implementation Speed | 8 | Graft source selection is an immediately modifiable clinical decision; does not require new drugs or regulatory approval |
| Evidence Strength | 6 | Large registry (n=2,900, EBMT) with multivariate analysis; retrospective design with unmeasured confounders and abstract-only access limits score |
Key quantitative result: PBSC vs. bone marrow: OS HR 0.67, LFS HR 0.71; NMA vs. RIC: no significant difference in OS, LFS, or NRM.
External validation: No independent external validation; EBMT registry data is the largest available dataset for this population. Retrospective only.
Main limitation: Retrospective registry design with inherent selection bias in graft source choice (centers may preferentially use PBSC in fitter patients). Abstract-only access precludes assessment of covariate adjustment completeness.
Equity implications: Elderly patients (≥65) are disproportionately underrepresented in prospective transplant trials; this registry study fills a critical gap. No sub-analysis by race/ethnicity reported. Resource-limited centers may lack access to PBSC processing infrastructure.
Evidence Maturity (revised): Potentially Practice-Changing — confirmed. The PBSC finding is immediately actionable for institutions already performing allo-HCT; the NMA vs. RIC equivalence finding resolves a longstanding clinical uncertainty.
Article 2 — Molica et al. — Pirtobrutinib vs. 2nd-gen covalent BTKi NMA in BTKi-naive R/R CLL (PMID 42323840)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | First Bayesian NMA providing indirect comparative evidence for pirtobrutinib vs. acalabrutinib/zanubrutinib in BTKi-naive setting; fills a genuine evidence gap |
| Clinical Relevance | 7 | Directly relevant to sequencing and drug selection in BTKi-naive R/R CLL; CV safety signal vs. zanubrutinib is actionable for cardiologically frail patients |
| Population Reach | 6 | CLL is the most common adult leukemia in the West; R/R BTKi-naive is a meaningful subset (~20,000 new CLL cases/yr in US) |
| Implementation Speed | 7 | Pirtobrutinib is FDA-approved; NMA findings can inform prescribing today pending head-to-head RCT data |
| Evidence Strength | 6 | Bayesian NMA of 3 RCTs (ELEVATE-RR, ALPINE, BRUIN-CLL-314); methodologically sound but indirect comparison with between-study heterogeneity acknowledged; abstract-only |
Key quantitative result: No significant PFS/OS difference vs. acalabrutinib or zanubrutinib; CV adverse event OR 0.52 favoring pirtobrutinib vs. zanubrutinib.
External validation: No direct head-to-head trial exists; NMA is the best available indirect comparison. The CV signal should be interpreted cautiously given unequal follow-up and event definitions across trials.
Main limitation: Indirect comparison methodology; heterogeneous patient populations across trials; n=814 total is modest for NMA; no individual-patient-level data.
Equity implications: BTKi toxicity profiles disproportionately affect older CLL patients with pre-existing cardiovascular disease. A CV-safer option benefits this high-comorbidity subgroup but pirtobrutinib's cost and reimbursement status may create access barriers.
Evidence Maturity (revised): Validated — confirmed as indirect evidence synthesis. Would benefit from prospective head-to-head confirmation; current evidence is sufficient to influence treatment preference discussions.
Article 3 — Aydogdu et al. — Preoperative tumor-informed ctDNA predicts nodal metastases in bladder cancer (PMID 42324366)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | First prospective study specifically testing tumor-informed ctDNA as a predictor of pathologic nodal status at cystectomy; high NPV finding is clinically novel |
| Clinical Relevance | 8 | Direct implication: ctDNA-negative patients may safely avoid pelvic lymph node dissection, potentially reducing surgical morbidity in ~68% of patients |
| Population Reach | 5 | Bladder cancer: ~83,000 new US cases/yr; radical cystectomy performed in ~15,000/yr; relevant subset but not a large-volume cancer overall |
| Implementation Speed | 5 | Tumor-informed ctDNA assays (e.g., Signatera) are commercially available; but evidence base is too small for practice change without a prospective multicenter trial |
| Evidence Strength | 5 | Prospective primary cohort (n=40) is underpowered; pooled validation (n=149) includes retrospective data; abstract-only; no independent external validation set |
Key quantitative result: Primary cohort: 86% sensitivity, 96% NPV. Pooled analysis (n=149): 92% NPV. Estimated 68% of patients would be eligible for LND omission.
External validation: Pooled descriptive analysis of published cohorts provides supporting data but is not an independent prospective validation; heterogeneity in assay platforms and patient selection likely.
Main limitation: Very small primary cohort (n=40) is the dominant limitation. Retrospective pooling for validation creates ascertainment and selection bias. NPV optimism may be inflated by low base-rate nodal disease in the study population. False negative rate (14%) could result in undertreated occult nodal disease with long-term survival consequences.
Equity implications: Tumor-informed ctDNA assays (personalized neoantigen-based panels) are currently expensive (~$2,000–5,000/test) and not universally reimbursed. Access is concentrated in academic centers. If validated, this technology would initially benefit well-insured patients at major cancer centers, with a significant access gap for underinsured and rural patients.
Evidence Maturity (revised): Downgraded from Validated → Exploratory-to-Validated (borderline). The NPV finding is promising but the primary cohort is too small and the pooled analysis too heterogeneous to meet "Validated" threshold. A prospective multicenter trial is essential before practice change.
Article 4 — Zhang et al. — ML risk stratification in elderly AML (PMID 42324513)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | ML models for AML prognostication are not novel; integration of immunophenotypic + genomic + therapeutic features in elderly patients is a worthwhile refinement |
| Clinical Relevance | 5 | C-index of 0.702 is modest; clinical applicability limited without external validation |
| Population Reach | 5 | Elderly AML is a high-unmet-need population but small absolute n=156 |
| Implementation Speed | 3 | Internal bootstrap validation only; years from clinical deployment |
| Evidence Strength | 4 | Retrospective single-center Chinese cohort, n=156, internal validation only; no external test set |
Key quantitative result: C-index 0.702 (MLP + Random Forest + Cox). Key predictors: TP53, CD13, IDH2.
Main limitation: Small single-center cohort with no external validation; bootstrap C-index may be optimistic.
Evidence Maturity: Exploratory — confirmed.
Article 5 — Hess et al. — Phase I oral azacitidine + R-ICE in r/r DLBCL (PMID 42324342)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Oral azacitidine as epigenetic sensitizer before salvage chemo in DLBCL is a conceptually novel strategy; limited prior Phase I data in this combination |
| Clinical Relevance | 5 | Phase I safety/feasibility only; no efficacy results reported; r/r DLBCL is a high-unmet-need indication |
| Population Reach | 5 | DLBCL is the most common aggressive lymphoma; R/R population is large and underserved |
| Implementation Speed | 3 | Phase I only; requires Phase II efficacy confirmation; 5+ years to routine practice |
| Evidence Strength | 5 | Phase I human trial is appropriate design for this stage; sample size not reported in abstract |
Main limitation: No efficacy data reported; sample size unknown from abstract.
Evidence Maturity: Exploratory — confirmed.
Article 6 — Ansari et al. — Bispecific Antibodies in Multiple Myeloma review (PMID 42323950)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Narrative review of already-approved agents; synthesizes existing knowledge rather than generating new evidence |
| Clinical Relevance | 6 | Clinically useful reference for RRMM management; BCMA/GPRC5D/FcRH5 agents are currently used in practice |
| Population Reach | 5 | RRMM is a substantial population (~35,000 new MM diagnoses/yr US); heavily pretreated patients represent ~15–20% |
| Implementation Speed | 6 | Agents already approved; review aids clinician adoption and sequencing decisions |
| Evidence Strength | 3 | Narrative review; no systematic search; no meta-analysis; moderate-impact journal |
Evidence Maturity: Validated (as a summary of existing approved therapies) — confirmed.
Article 7 — Griesshammer et al. — German ONKOPEDIA Myelofibrosis Guideline 2025 (PMID 42324205)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Guideline synthesis; no primary data; consolidates existing evidence |
| Clinical Relevance | 8 | High-value clinical tool for MF management; incorporates recent treatment advances (pacritinib, fedratinib, imetelstat) and updated risk stratification |
| Population Reach | 4 | MF is a relatively rare MPN (~3/100,000 prevalence); primarily relevant to German-speaking countries but International Journal of Cancer broadens reach |
| Implementation Speed | 9 | Guidelines are immediately adoptable; published in a high-impact international journal |
| Evidence Strength | 6 | Expert consensus guideline from authoritative DGHO panel; well-established methodology for practice guidelines; abstract-only |
Evidence Maturity: Potentially Practice-Changing — confirmed for jurisdictions adopting DGHO-aligned practice.
Article 8 — Toledano-Fonseca et al. — Tumour sidedness modulates liquid biopsy prognostic value in CRC (PMID 42324399)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Tumour sidedness effects are known for tissue biomarkers; application to ctDNA/cfDNA prognostics is a meaningful and underexplored refinement |
| Clinical Relevance | 7 | Immediately actionable: clinicians interpreting liquid biopsy results in mCRC should account for tumour sidedness |
| Population Reach | 7 | CRC is the 2nd leading cause of cancer death globally; liquid biopsy use in mCRC is growing rapidly |
| Implementation Speed | 7 | No new tests required; adjusts interpretation of existing cfDNA assays |
| Evidence Strength | 6 | Prospective cohort, n=232; single-center Spanish study; abstract-only; no independent validation cohort |
Key quantitative result: Circulating RAS mutations and cfDNA concentration predict worse outcomes in left-sided but not right-sided mCRC.
Evidence Maturity: Validated — confirmed, with the caveat that multicenter replication would strengthen the interpretation framework.
Article 9 — Csizmarik et al. — UCA1 cfDNA copy number gain predicts ENZA resistance in mCRPC (PMID 42324329)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | UCA1 copy number gain as a treatment-specific cfDNA resistance biomarker is novel; dual cell-line discovery + clinical validation approach is methodologically sound |
| Clinical Relevance | 4 | Small n=20/arm severely limits clinical applicability; hypothesis-generating only at this stage |
| Population Reach | 6 | mCRPC is a large global population (~34,000 deaths/yr US); enzalutamide resistance is a universal clinical challenge |
| Implementation Speed | 3 | Very early stage; ddPCR assay is technically available but clinical validation far from complete |
| Evidence Strength | 4 | Very small clinical cohort (n=20 per arm); cell-line discovery data supports but cannot validate clinical relevance; Sci Rep open access |
Evidence Maturity: Exploratory — confirmed.
Article 10 — Benjamin et al. — Centralization of lung cancer screening and adherence in VHA (PMID 42323868)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Centralization of screening programs improving adherence is conceptually unsurprising; the scale (n=146K) and difference-in-differences methodology add methodological value |
| Clinical Relevance | 6 | Directly informs LCS program design; relevant to healthcare administrators and policymakers |
| Population Reach | 8 | Lung cancer kills ~130,000 Americans/yr; LCS eligibility pool is ~14 million; adherence gaps affect millions |
| Implementation Speed | 6 | Program restructuring is feasible at system level; VHA findings may not translate directly to community/private settings |
| Evidence Strength | 7 | Large nationwide cohort (n=146K), difference-in-differences design adds causal inference rigor; VHA system data is robust |
Key quantitative result: Hybrid centralization OR 1.16; full centralization OR 1.13 for first follow-up adherence. Overall adherence 58.5% even in best programs.
Equity implications: Black and rural Veterans showed lower adherence regardless of program type — a persistent equity gap that centralization alone does not resolve. These are the populations with highest lung cancer mortality burden and lowest screening penetration.
Evidence Maturity: Validated — confirmed.
Article 11 — Akbar et al. — Extracellular vesicles as biomarkers in NSCLC review (PMID 42323710)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | EV biomarker reviews are numerous; this provides a useful synthesis but limited novel insight |
| Clinical Relevance | 3 | Field is pre-clinical/early exploratory; no clinical implementation pathway described |
| Population Reach | 7 | NSCLC is one of the highest-burden cancers globally (~250,000 US cases/yr) |
| Implementation Speed | 2 | Years from clinical standardization; regulatory, analytical, and clinical validation barriers remain |
| Evidence Strength | 3 | Narrative review; no primary data; no systematic methodology |
Evidence Maturity: Exploratory — confirmed.
Article 12 — Onaga et al. — AI screening for NTRK fusion-positive salivary gland tumors (PMID 42323990)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | First AI histopathology-based NTRK fusion screening tool for salivary gland cancer; Luigi-Oral is a novel application |
| Clinical Relevance | 7 | Directly enables identification of patients eligible for TRK inhibitors (larotrectinib/entrectinib); IHC-comparable performance is clinically significant |
| Population Reach | 4 | Salivary gland cancer is rare (~3,000 US cases/yr); NTRK-positive subset is ~5% (but ~90% in secretory carcinoma); population reach is limited but unmet need is high |
| Implementation Speed | 5 | Digital pathology infrastructure required; AI model not yet externally validated; single-center Japan |
| Evidence Strength | 6 | Retrospective validation, n=273, single high-quality center (National Cancer Center Japan), FISH as gold standard; needs multicenter validation |
Key quantitative result: Sensitivity 85.7%, specificity 93.2% vs. FISH gold standard.
Equity implications: Access to NTRK testing is severely limited in low- and middle-income countries where FISH and IHC are costly. An H&E-based AI tool could democratize access to targeted therapy selection if externally validated and made available open-source.
Evidence Maturity: Validated (single-center) — downgrade cautioned; would revise to Exploratory-to-Validated pending multicenter replication.
Article 13 — Khadiullina et al. — Allogeneic CAR-T cell therapies review (PMID 42324475)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Allo-CAR-T reviews are proliferating; balanced assessment of clinical barriers is useful but not distinctive |
| Clinical Relevance | 4 | Field is early; no immediately actionable clinical findings |
| Population Reach | 7 | CAR-T indications span multiple high-incidence hematologic and solid malignancies |
| Implementation Speed | 2 | Manufacturing and regulatory barriers remain substantial; 5–10+ years |
| Evidence Strength | 3 | Narrative review, moderate-impact journal |
Evidence Maturity: Exploratory — confirmed.
Article 14 — Chien et al. — Smoking-associated gut microbiota shapes ICI response in NSCLC (PMID 42324435)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Mechanistic link between smoking-specific microbiome shifts (Bifidobacterium longum reduction, Gammaproteobacteria enrichment) and ICI response is a novel observation in a prospective dataset |
| Clinical Relevance | 5 | Hypothesis-generating; microbiome modulation for ICI augmentation is years from clinical use; 16S rRNA (not shotgun metagenomics) limits resolution |
| Population Reach | 7 | NSCLC + ICI is one of the largest oncology treatment populations globally |
| Implementation Speed | 3 | Requires mechanistic validation and intervention trials before clinical application |
| Evidence Strength | 5 | Prospective cohort, n=225; 16S rRNA sequencing (not gold standard); functional predictions are computational |
Evidence Maturity: Exploratory — confirmed.
Article 15 — Shahnam et al. — Concomitant medications and ICI outcomes in sarcoma (PMID 42324568)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | First systematic analysis of concomitant medication effects on ICI outcomes across multiple Phase II sarcoma trials; statin and anti-infective signals are clinically novel |
| Clinical Relevance | 6 | Informs patient counseling and potentially trial stratification; pharmacological signals (statins, opioids) are actionable in principle but post hoc design limits causal inference |
| Population Reach | 4 | Sarcoma is a rare malignancy (~13,000 US cases/yr); ICI use in sarcoma is expanding but not universal |
| Implementation Speed | 5 | Statin and opioid management changes are immediately feasible if confirmed; but post hoc nature requires prospective validation |
| Evidence Strength | 6 | Pooled analysis of 7 MSK Phase II trials, n=321; MSK institutional quality; adjusted HRs reported; post hoc design and potential confounding acknowledged |
Key quantitative result: Anti-infectives: aHR 1.54 for PFS; statins: aHR 0.64 for PFS; opioids: aHR 1.71 for OS.
Evidence Maturity: Exploratory — confirmed; hypothesis-generating. Signals warrant prospective evaluation.
Article 16 — Choi et al. — SGLT2i associated with lower gout risk: cohort + Mendelian randomization (PMID 42324202)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | SGLT2i uricosuria and gout-protective effect is biologically plausible and previously reported; this study adds MR causal evidence in a large Korean cohort |
| Clinical Relevance | 8 | Directly informs prescribing in diabetic patients with comorbid gout/hyperuricemia; reinforces SGLT2i as preferred agent in this group |
| Population Reach | 9 | T2DM + gout/hyperuricemia affects tens of millions globally; SGLT2i are widely prescribed |
| Implementation Speed | 9 | SGLT2i already in widespread clinical use; no new agents or procedures required |
| Evidence Strength | 7 | Large PS-matched cohort (n=41,732) + Mendelian randomization causal validation; Korean database study with ethnic generalizability limitations |
Key quantitative result: HR 0.80 (95% CI 0.76–0.84) for incident gout; MR OR 0.10 per 1-SD HbA1c reduction via SLC5A2.
Evidence Maturity: Validated — confirmed. MR strengthens causal interpretation substantially.
Article 17 — Tomoi et al. — SGLT2i reduces MACE in DM+PAD after endovascular therapy (PMID 42323971)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Extends known SGLT2i CV benefit to a specific high-risk PAD post-revascularization context; no large RCT data in this specific subgroup |
| Clinical Relevance | 7 | Directly addresses a clinical gap: SGLT2i evidence in PAD with completed revascularization; reassuringly no increased limb events |
| Population Reach | 6 | DM+PAD is a large and growing population (~8–10 million US); endovascular therapy is the predominant revascularization approach |
| Implementation Speed | 7 | SGLT2i are widely available; findings support extending existing prescribing to post-EVT patients |
| Evidence Strength | 5 | Retrospective single-center Japanese study, n=470, PS matching applied; abstract-only; generalizability to non-Japanese populations uncertain |
Evidence Maturity: Validated — confirmed (with single-center retrospective caveats).
Article 18 — Sun et al. — IR indices and cardiometabolic multimorbidity in MASLD (UK Biobank) (PMID 42324458)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | IR index comparison in MASLD is a refinement of existing cardiometabolic risk literature; TyG-WHtR superiority is a new finding with practical value |
| Clinical Relevance | 7 | TyG-WHtR is a calculable, actionable clinical index; findings directly support which IR metric to use for MASLD risk stratification |
| Population Reach | 9 | MASLD affects ~25–38% of the global population; cardiometabolic multimorbidity risk stratification is broadly applicable |
| Implementation Speed | 7 | TyG-WHtR requires only triglycerides + waist/height measurements; immediately calculable in clinical practice |
| Evidence Strength | 8 | Very large prospective cohort (n=109,604), UK Biobank, 15.9 years follow-up, multi-state modeling; robust design |
Key quantitative result: TyG-WHtR: HR 2.70 (highest vs. lowest quartile) for CMM in MASLD.
Evidence Maturity: Validated — confirmed. Large well-designed prospective study with long follow-up.
Article 19 — Han et al. — Stem cell-derived EVs for rare diseases: translational framework (PMID 42324126)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Framework proposal is conceptually useful but not based on new primary data; EV therapy for rare diseases is an active but early field |
| Clinical Relevance | 3 | No clinical data; preclinical/conceptual framework only |
| Population Reach | 6 | Collectively, rare diseases affect 300+ million people globally; high unmet need |
| Implementation Speed | 1 | Preclinical stage; manufacturing, regulatory, and clinical validation barriers are substantial |
| Evidence Strength | 2 | Narrative review with framework proposal; no clinical or preclinical data presented |
Evidence Maturity: Exploratory — confirmed.
Article 20 — Velu et al. — EMDR vs. KIDNET RCT in refugee children with PTSD (PMID 42324567)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | First head-to-head RCT directly comparing EMDR and KIDNET in refugee minors; EMDR superiority with fewer sessions is a novel quantified finding in this population |
| Clinical Relevance | 7 | Directly informs mental health service design for refugee children; EMDR's session efficiency advantage has real-world resource implications |
| Population Reach | 7 | Global refugee children with PTSD: >100 million displaced persons worldwide, a large proportion of whom are children with high PTSD prevalence |
| Implementation Speed | 7 | Both treatments are deliverable now; findings can immediately influence protocol selection in existing services |
| Evidence Strength | 7 | Three-arm RCT, registered trial (NL-OMON44793), clinician-rated outcomes; n=96 is small but appropriate for this difficult-to-reach population |
Key quantitative result: EMDR: d=1.31 vs. waitlist; KIDNET: d=0.94; EMDR vs. KIDNET: d=−0.38; mean sessions EMDR 6.6 vs. KIDNET 9.1.
Equity implications: This is entirely an equity-focused study — refugee children with PTSD are among the most underserved mental health populations globally. The session efficiency finding has direct cost and access implications for under-resourced refugee service settings.
Evidence Maturity: Validated — confirmed.
PHASE 3 — Ranking
Composite Impact Score Formula
Clinical Relevance (30%) + Population Reach (25%) + Scientific Novelty (20%) + Implementation Speed (15%) + Evidence Strength (10%)
Conflict/Agreement Summary
Two articles address SGLT2 inhibitors (Articles 16 and 17) and are complementary rather than conflicting: Article 16 focuses on incident gout prevention in T2DM with MR causal evidence; Article 17 focuses on MACE reduction in DM+PAD post-EVT. Both reinforce the pleiotropic benefit profile of SGLT2i in different high-risk subgroups. No direct conflicts detected across the batch.
Ranked Table
| Rank | Article | Flag | Impact Score | Clinical Relevance (30%) | Population Reach (25%) | Scientific Novelty (20%) | Implementation Speed (15%) | Evidence Strength (10%) | OpenClaw Triage Score | Study Design | Rank Justification | Why It Matters |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 🥇 1 | Art. 16 — Choi et al., SGLT2i & gout risk (PMID 42324202) | 🟢 | 7.73 | 8 | 9 | 6 | 9 | 7 | 7 | PS-matched cohort + MR | The largest study to date combining propensity-matched cohort (n=41,732) and Mendelian randomization causal validation for SGLT2i-associated gout prevention. High population reach (T2DM + gout/hyperuricemia affects tens of millions), strong evidence design, and immediate implementability — no new drugs or infrastructure required, just prescriber awareness. The MR evidence materially strengthens causal inference beyond what observational data alone could provide. | For diabetic patients who also suffer from gout — a painful and common comorbidity — SGLT2 inhibitors already prescribed for glucose, heart, and kidney protection may now be the preferred choice to prevent gout attacks too. |
| 🥈 2 | Art. 18 — Sun et al., IR indices & CMM in MASLD (PMID 42324458) | 🟢 | 7.60 | 7 | 9 | 6 | 7 | 8 | 7 | Prospective cohort + multi-state model | Exceptional study size (n=109,604, UK Biobank, 15.9 years) gives this article one of the strongest evidence bases in the batch. TyG-WHtR is calculable from routine clinical data with no additional cost, making it immediately implementable for MASLD cardiometabolic risk stratification. Population reach is vast given the global MASLD epidemic. Narrowly trails Article 16 on implementation speed and clinical novelty. | One in four people globally has metabolic fatty liver disease. A simple waist-to-height ratio combined with triglycerides can identify who is headed for heart disease, diabetes, and multimorbidity — potentially years before symptoms appear. |
| 🥉 3 | Art. 1 — Kanellopoulos et al., NMA vs. RIC in elderly AML (PMID 42324362) | 🟢 | 7.20 | 8 | 6 | 7 | 8 | 6 | 9 | Retrospective registry (EBMT, n=2,900) | The largest comparative conditioning study in elderly AML transplant recipients to date, with a highly actionable finding: PBSC grafts confer ~33% OS improvement (HR 0.67) over bone marrow. Conditioning equivalence resolves a longstanding clinical debate. Ranks third due to narrower population reach (elderly AML transplant candidates) and retrospective design limiting evidence strength below the top two. The PBSC finding is ready for immediate practice consideration and can be implemented without regulatory change. | For older patients with AML who are well enough to receive a stem cell transplant, choosing peripheral blood stem cells over bone marrow as the graft source may meaningfully improve their chances of survival — a decision that can be made today. |
| 4 | Art. 10 — Benjamin et al., LCS centralization in VHA (PMID 42323868) | 🟡 | 6.65 | 6 | 8 | 5 | 6 | 7 | 6 | Retrospective cohort, DiD (n=146,321) | Exceptional scale and rigorous quasi-experimental design make this the strongest population-health finding in the batch. Ranks 4th due to more modest clinical relevance (screening program design vs. direct patient care) and incremental novelty. The persistent equity gap — Black and rural Veterans not fully served even by centralized programs — is a critical finding for health systems. | More than 140,000 Veterans showed that how you organize a lung cancer screening program determines whether patients actually follow through. Centralization helps — but it's not enough for the most underserved groups. |
| 5 | Art. 20 — Velu et al., EMDR vs. KIDNET RCT in refugee children (PMID 42324567) | 🟡 | 6.60 | 7 | 7 | 6 | 7 | 7 | 7 | Three-arm RCT | The only RCT in the batch for a completely underserved population. EMDR's d=1.31 effect size is large; the session efficiency advantage (6.6 vs. 9.1 sessions) has direct cost-access implications for underfunded refugee mental health services. Ranks 5th due to smaller population reach relative to cardiovascular topics and being outside core watchlist topics. | With over 100 million displaced people worldwide, many of them children with PTSD, this RCT shows that EMDR works faster and at least as well as the established KIDNET therapy — an important finding for resource-stretched refugee mental health programs. |
| 6 | Art. 2 — Molica et al., Pirtobrutinib vs. 2nd-gen BTKi NMA (PMID 42323840) | 🟢 | 6.60 | 7 | 6 | 7 | 7 | 6 | 8 | Bayesian NMA of RCTs | First indirect comparative evidence for pirtobrutinib positioning in BTKi-naive CLL with a clinically meaningful CV safety signal vs. zanubrutinib. Ranks 6th due to indirect comparison limitations and moderate population size. The CV safety advantage is immediately actionable for cardiologically frail CLL patients. Tie with Article 20 broken by Clinical Relevance (7=7), then Evidence Strength (6=7→20 ranks higher). Re-checking: Art. 20 Evidence Strength = 7, Art. 2 = 6. Article 20 ranks 5th. | For CLL patients with heart problems who need a BTK inhibitor, pirtobrutinib may offer a safer cardiovascular profile than zanubrutinib without sacrificing efficacy — a finding with immediate prescribing implications. |
| 7 | Art. 17 — Tomoi et al., SGLT2i in DM+PAD post-EVT (PMID 42323971) | 🟢 | 6.45 | 7 | 6 | 6 | 7 | 5 | 6 | Retrospective cohort, PS-matched | Extends SGLT2i CV benefit to a specific high-risk gap population (DM+PAD post-EVT) with no increased limb events. Ranks 7th due to single-center retrospective design and narrower reach than the gout study. Clinically reinforces SGLT2i prescribing in peripheral vascular disease patients. | Diabetic patients who've had a procedure to open blocked leg arteries are at high risk for heart attacks and strokes. SGLT2 inhibitors appear to reduce that risk — without making leg problems worse. |
| 8 | Art. 3 — Aydogdu et al., ctDNA predicts nodal status in bladder cancer (PMID 42324366) | 🔴 | 6.25 | 8 | 5 | 8 | 5 | 5 | 8 | Prospective cohort + pooled analysis (n=40+149) | High scientific novelty and clinical relevance (LND omission strategy) are tempered by the very small primary cohort (n=40) and retrospective pooled validation. Cannot rank higher due to Evidence Strength cap concern (5/10). Concept is compelling; prospective multicenter validation is needed urgently. | A blood test before bladder cancer surgery may safely identify the 68% of patients who could skip lymph node removal — avoiding surgical complications without missing hidden cancer spread. The evidence is promising but needs a larger confirmatory trial. |
| 9 | Art. 8 — Toledano-Fonseca et al., Tumour sidedness & liquid biopsy in mCRC (PMID 42324399) | 🟢 | 6.25 | 7 | 7 | 6 | 7 | 6 | 6 | Prospective cohort (n=232) | Important interpretive refinement for ctDNA/cfDNA in mCRC clinical practice. High implementation speed (no new assays needed, just modified interpretation) and broad population reach. Ranks 9th due to single-center design and need for independent replication. | Where a colorectal tumor starts — right side vs. left side of the colon — changes what a liquid biopsy result actually means. Ignoring sidedness may lead to misjudging a patient's prognosis or treatment trajectory. |
| 10 | Art. 7 — Griesshammer et al., ONKOPEDIA MF Guideline 2025 (PMID 42324205) | 🟢 | 6.00 | 8 | 4 | 3 | 9 | 6 | 7 | Clinical practice guideline | Immediately implementable expert guideline with high clinical relevance for MF management. Ranks 10th due to low novelty (synthesis of existing evidence) and limited population reach for a rare disease. Highest implementation speed in the batch. | The updated German myelofibrosis guideline reflects the latest treatments and risk tools — a practical clinical reference for physicians managing this difficult bone marrow disease. |
| 11 | Art. 15 — Shahnam et al., Concomitant medications & ICI outcomes in sarcoma (PMID 42324568) | ⚪ | 5.55 | 6 | 4 | 7 | 5 | 6 | 7 | Pooled post hoc analysis (7 Phase II, n=321) | Novel hypothesis-generating signals from a credible MSK multi-trial dataset. Post hoc design and confounding potential limit evidence strength and clinical implementability. Statin and opioid signals warrant prospective evaluation. | What patients are taking alongside immunotherapy may matter as much as the cancer itself — statins appeared protective and opioids appeared harmful in sarcoma ICI trials. These signals deserve prospective testing. |
| 12 | Art. 12 — Onaga et al., AI screening for NTRK+ salivary gland tumors (PMID 42323990) | 🟢 | 5.50 | 7 | 4 | 7 | 5 | 6 | 7 | Retrospective validation (n=273) | High novelty and clinical relevance for a rare cancer with actionable targeted therapy; limited by small rare-disease population and single-center design. Potential to democratize NTRK testing in resource-limited settings is a significant long-term equity benefit. | An AI system that reads routine pathology slides can flag rare NTRK gene fusions in salivary gland tumors — potentially replacing expensive genetic tests and helping match more patients to targeted therapies worldwide. |
| 13 | Art. 14 — Chien et al., Gut microbiota & ICI response in NSCLC (PMID 42324435) | ⚪ | 5.35 | 5 | 7 | 7 | 3 | 5 | 6 | Prospective cohort (n=225) | Mechanistically interesting and prospective, but 16S rRNA limits resolution and causal pathways are computational. Population reach is large but clinical translation is distant. | Smokers' gut bacteria may explain why some NSCLC patients respond better to immunotherapy — a counterintuitive finding that could eventually point to microbiome-based strategies for improving ICI response. |
| 14 | Art. 5 — Hess et al., Oral azacitidine + R-ICE in r/r DLBCL (PMID 42324342) | 🟠 | 5.15 | 5 | 5 | 7 | 3 | 5 | 7 | Phase I clinical trial | Important early-stage safety data for a novel epigenetic sensitization strategy in a high-unmet-need indication. Phase I limits clinical relevance and speed. Efficacy data pending. | Adding an oral epigenetic drug to salvage chemotherapy in relapsed aggressive lymphoma is feasible and safe — the first step toward testing whether it can actually improve response rates. |
| 15 | Art. 4 — Zhang et al., ML risk stratification in elderly AML (PMID 42324513) | ⚪ | 4.80 | 5 | 5 | 6 | 3 | 4 | 7 | Retrospective ML model (n=156) | Addresses a real unmet need but modest C-index (0.702) and single-center Chinese cohort with no external validation prevent higher ranking. Exploratory contribution to the field. | A machine learning model combining genetic and immune markers shows early promise for predicting which elderly AML patients will fare best — but it needs testing in far larger, more diverse patient groups. |
| 16 | Art. 9 — Csizmarik et al., UCA1 cfDNA predicts ENZA resistance in mCRPC (PMID 42324329) | ⚪ | 4.75 | 4 | 6 | 7 | 3 | 4 | 5 | Translational biomarker study (n=80) | Novel cfDNA biomarker with a compelling discovery-to-clinical-validation pipeline, but n=20/arm is too small for any clinical conclusions. | A blood-based marker may predict which hormonal drug will stop working in advanced prostate cancer — a finding with real clinical potential that needs much larger study to confirm. |
| 17 | Art. 6 — Ansari et al., Bispecific antibodies in MM review (PMID 42323950) | 🟢 | 4.75 | 6 | 5 | 4 | 6 | 3 | 6 | Narrative review | Clinically useful reference for an actively evolving area of practice; limited impact as a narrative review in a moderate-impact journal. | A practical overview of the newest bispecific antibody options for triple-refractory myeloma — useful for clinicians navigating a rapidly expanding treatment landscape. |
| 18 | Art. 13 — Khadiullina et al., Allogeneic CAR-T review (PMID 42324475) | ⚪ | 4.35 | 4 | 7 | 5 | 2 | 3 | 6 | Narrative review | Balanced review of a promising but early-stage field; limited clinical relevance at current development stage. | Off-the-shelf CAR-T cells are advancing but still face major hurdles — this review maps the challenges and engineering solutions without overpromising. |
| 19 | Art. 11 — Akbar et al., EVs as biomarkers in NSCLC review (PMID 42323710) | ⬜ | 3.85 | 3 | 7 | 4 | 2 | 3 | 5 | Narrative review | Large population reach for NSCLC but early-stage field review with no primary data and no near-term implementation pathway. | Tiny cell-derived particles in blood hold long-term promise for lung cancer monitoring, but the field needs standardization and large-scale clinical trials before this becomes a clinical tool. |
| 20 | Art. 19 — Han et al., Stem cell-derived EVs for rare diseases framework (PMID 42324126) | 🟡 | 3.45 | 3 | 6 | 5 | 1 | 2 | 5 | Narrative review + framework | Conceptually valuable for rare disease drug development planning but entirely preclinical; no clinical data; lowest implementation speed in the batch. | A new framework helps researchers prioritize which rare diseases to target with stem cell-derived particles — useful for field navigation but far from the clinic. |